re:news received

It's good to see new enthusiasm in this stock.I had previously missed Korean 45k in sale-apologies[small things are easy to miss].
Once again,I would suggest that China would be the most promising Asian market:having experience living in HK,I know that lung-related complaints are epidemic-the increasing pollution will ensure this situation only gets worse.
These products only monitor the asthmatic disease.You could perceive that as problematic:other products have a more direct impact on the comfort of the sufferer;the general public will not embrace the devices,leaving only the niche markets of specialized medical services.Or you can see this as it's strength:it doesn't challenge established markets.It promises to ride the back of the emerging market of 'hospital to home' services.If the product became part of the standard home management model,KSX would indeed,TwinTurboCelica,be a "dream not a nightmare".Also the present "little share price" would be,in 3 or 4 years,alot closer to Resmed's.

Also again,I would suggest that Government subsidies for KSX products would be the 'golden egg' that maybe awaits if everything goes according to script.

Good Luck to all holders